Skip to main content
Stefan Faderl, MD, Oncology, Palo Alto, CA

StefanH.FaderlMD

Oncology Palo Alto, CA

Hematologic Oncology

Chief, Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center

Dr. Faderl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Faderl's full profile

Already have an account?

  • Office

    3170 Porter Drive
    Palo Alto, CA 94304

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
  • Steward Carney Hospital
    Steward Carney HospitalResidency, Internal Medicine, 1993 - 1996
  • Ludwig Maximilian University of Munich Faculty of Medicine
    Ludwig Maximilian University of Munich Faculty of MedicineClass of 1990

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1999 - 2025
  • NJ State Medical License
    NJ State Medical License 2013 - 2017
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
    Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 ...
    Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
    Stefan Faderl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition
    John Theurer Cancer Center (JTCC) Researchers to Present 52 Abstracts Across Hematological Malignancies at the 2020 American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 4th, 2020